Search

Displaying results 4201 - 4210 of 6951 in total
  1. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    The recommended dose of xylitol for dental caries prevention is 6–10 g/day, and most adults can tolerate 40 g/day without adverse events [A22081].

  2. Drug

    HCV-086

    go.drugbank.com/drugs/DB05884
    Experimental

    HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.

  3. Drug

    BL-1020

    go.drugbank.com/drugs/DB05687
    Investigational

    BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).

  4. Drug

    Potassium sulfate

    go.drugbank.com/drugs/DB14499
    Approved

  5. Drug

    Toloxatone

    go.drugbank.com/drugs/DB09245
    Experimental

    Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) .

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Navarixin

    go.drugbank.com/drugs/DB11711
    Investigational

    Navarixin has been investigated for the treatment of Asthma.

  7. Drug

    Sarcosine

    go.drugbank.com/drugs/DB12519
    Investigational

    Sarcosine has been investigated for the treatment of Schizophrenia.

  8. Drug

    Pyronaridine

    go.drugbank.com/drugs/DB12975
    Investigational

    Pyronaridine has been investigated for the treatment of Malaria.

  9. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    [L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. … Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    Milveterol

    go.drugbank.com/drugs/DB05043
    Investigational

    GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.